Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11430938 | 0.83 | GSK3B (0.57) | GSK3BNPC1HPGDRAB9AHDAC1 | |
| SCHEMBL11430934 | 0.83 | GSK3B (0.57) | GSK3BNPC1HPGDRAB9AHDAC1 | |
| SCHEMBL7044827 | 0.82 | RAB9A (0.50) | GSK3BNPC1HPGDRAB9AHDAC1 | |
| SCHEMBL28573354 | 0.80 | HPGD (0.49) | GSK3BNPC1HPGDRAB9AHDAC1 | |
| SCHEMBL10465722 | 0.79 | GSK3B (0.53) | GSK3BNPC1HPGDRAB9AHDAC1 | |
| SCHEMBL11801259 | 0.79 | RAB9A (0.62) | GSK3BNPC1HPGDRAB9AHDAC1 | |
| SCHEMBL11757716 | 0.79 | ALDH1A1 (0.62) | GSK3BNPC1HPGDRAB9AHDAC1 | |
| SCHEMBL10465723 | 0.79 | GSK3B (0.53) | GSK3BNPC1HPGDRAB9AHDAC1 | |
| SCHEMBL14735749 | 0.79 | NPC1 (0.58) | NPC1RAB9AKDM4EGAAMAPT | |
| SCHEMBL241664 | 0.78 | GSK3B (0.70) | GSK3BHDAC1HDAC8HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703181-B1 | COMPRISING AT LEAST ONE OF: IMIDAZOLE COMPOUND, AN ALANINE COMPOUND, AN ADENINE COMPOUND, AN ADENOSINE COMPOUND, AND A QUATERNARY AMMONIUM SALT COMPOUND, AND WHICH INCREASES MISCIBILITY IN A RESIST FILM | KABUSHIKI KAISHA TOSHIBA (JP) | 2004-03-09 | — | — | US | claimed |
| US-12551570-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2026-02-17 | — | — | US | disclosed |
| US-12479927-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-20250213712-A1 | ANTIBODY DRUG CONJUGATES COMPRISING CAMPTOTHECIN DERIVATIVES AND USES THEREOF | INTOCELL, INC. (KR) | 2025-07-03 | — | — | US | disclosed |
| CN-119838020-A | Antibody drug conjugates comprising toxins having polar groups and uses thereof | 尹图赛利有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-12274898-B2 | Substituted benzodiazepines as antibody-drug conjugates | INTOCELL, INC. (KR) | 2025-04-15 | — | — | US | disclosed |
| EP-4452328-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | Intocell, Inc. (KR) | 2024-10-30 | — | — | EP | disclosed |
| CN-118414170-A | Antibody drug conjugates comprising toxins having polar groups and uses thereof | 尹图赛利有限公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20230406877-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2023-12-21 | — | — | US | disclosed |
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-6162614-A | Sugar ester derivatives, reagents for measurement of hydrolase activity and methods for measurement of hydrolase activity | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2000-12-19 | — | — | US | disclosed |
| US-5814432-A | FORMING RADIATION SENSITIVE LAYER ON SUBSTRATE, CONTAINS FIRST COMPONENT WHICH GENERATES ACID BY CHEMICAL RADIATION AND SECOND COMPONENT THAT HAS BOND BEING DECOMPOSED BY GENERATED ACID | KABUSHIKI KAISHA TOSHIBA (JP) | 1998-09-29 | — | — | US | disclosed |
| US-RE35821-E | Pattern forming method including the formation of an acidic coating layer on the radiation-sensitive layer | KABUSHIKI KAISHA TOSHIBA (JP) | 1998-06-09 | — | — | US | disclosed |
| US-5744281-A | P-HYDROXYSTYRENE POLYMER | KABUSHIKI KAISHA TOSHIBA (JP) | 1998-04-28 | — | — | US | disclosed |
| EP-0346912-B1 | Sugar ester derivatives, reagents for measurement of hydrolase activity and methods for measurement of hydrolase activity | TOYO BOSEKI (JP) | 1997-12-17 | — | — | EP | disclosed |
| US-5658706-A | CONTAINING COMPOUND WHICH DECOMPOSES INTO AN ACID | KABUSHIKI KAISHA TOSHIBA (JP) | 1997-08-19 | — | — | US | disclosed |
| US-5580702-A | COMPRISING A PHOTOSENSITIVE ACID-GENERATING COMPOUND AND A COPOLYMER OF P-HYDROXYSTYRENE AND AN ESTER OF P-CARBOXYMETHOXYSTYRENE; NONTOXIC; STEEP WALLS; HIGH SPEED; SEMICONDUCTORS | KABUSHIKI KAISHA TOSHIBA (JP) | 1996-12-03 | — | — | US | disclosed |
| US-5403695-A | Photolithography; high resolution; semiconductors | KABUSHIKI KAISHA TOSHIBA (JP) | 1995-04-04 | — | — | US | disclosed |
| US-5326675-A | Pattern forming method including the formation of an acidic coating layer on the radiation-sensitive layer | KABUSHIKI KAISHA TOSHIBA (JP) | 1994-07-05 | — | — | US | disclosed |
| EP-0346912-A2 | Sugar ester derivatives, reagents for measurement of hydrolase activity and methods for measurement of hydrolase activity | Toyo Boseki Kabushiki Kaisha (JP) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | GSK3B 715/4885NPC1 1207/4885HPGD 471/4885 |
| US-20250213712-A1 | ANTIBODY DRUG CONJUGATES COMPRISING CAMPTOTHECIN DERIVATIVES AND USES THEREOF | CD47, TOP2A, SSB | GSK3B 2830/4885NPC1 3651/4885HPGD 1599/4885 |
| US-12551570-B2 | Compounds comprising cleavable linker and uses thereof | FCGR2A, FCGR3B, FCGR1A | GSK3B 4009/4885NPC1 2805/4885HPGD 4856/4885 |
| US-20230406877-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | VIP, ANTXR2, TNFRSF9 | GSK3B 4462/4885NPC1 4849/4885HPGD 2968/4885 |
| US-12479927-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | GSK3B 4462/4885NPC1 4849/4885HPGD 2968/4885 |
| US-12274898-B2 | Substituted benzodiazepines as antibody-drug conjugates | GABRA3, GABRA6, GABRA4 | GSK3B 506/4885NPC1 1251/4885HPGD 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.